141 related articles for article (PubMed ID: 4374338)
1. Investigations on the use of testosterone oenanthate as a male contraceptive agent.
Mauss J; Börsch G; Richter E; Bormacher K
Contraception; 1974 Sep; 10(3):281-9. PubMed ID: 4374338
[TBL] [Abstract][Full Text] [Related]
2. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
3. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosterone.
Anderson RA; Wallace AM; Wu FC
J Clin Endocrinol Metab; 1996 Mar; 81(3):902-8. PubMed ID: 8772548
[TBL] [Abstract][Full Text] [Related]
4. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
Matsumoto AM
J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
[TBL] [Abstract][Full Text] [Related]
5. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido.
Pavlou SN; Brewer K; Farley MG; Lindner J; Bastias MC; Rogers BJ; Swift LL; Rivier JE; Vale WW; Conn PM
J Clin Endocrinol Metab; 1991 Dec; 73(6):1360-9. PubMed ID: 1955518
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of long-term treatment with levo-norgestrel and testosterone enanthate in normal men.
Foegh M; Nicol K; Petersen IB; Schou G
Contraception; 1980 Jun; 21(6):631-40. PubMed ID: 6775869
[TBL] [Abstract][Full Text] [Related]
7. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
Wallace EM; Gow SM; Wu FC
J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
[TBL] [Abstract][Full Text] [Related]
8. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.
Behre HM; Nashan D; Hubert W; Nieschlag E
J Clin Endocrinol Metab; 1992 Jan; 74(1):84-90. PubMed ID: 1727833
[TBL] [Abstract][Full Text] [Related]
9. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate.
Tom L; Bhasin S; Salameh W; Steiner B; Peterson M; Sokol RZ; Rivier J; Vale W; Swerdloff RS
J Clin Endocrinol Metab; 1992 Aug; 75(2):476-83. PubMed ID: 1639948
[TBL] [Abstract][Full Text] [Related]
10. Sperm motion parameters after suppression of spermatogenesis with a gonadotropin-releasing hormone antagonist plus testosterone supplementation.
Bastias MC; Kamijo H; Pavlou SN
Fertil Steril; 1993 Jun; 59(6):1261-5. PubMed ID: 8495775
[TBL] [Abstract][Full Text] [Related]
11. Study of medroxyprogesterone acetate and testosterone enanthate as a male contraceptive.
Brenner PF; Mishell DR; Bernstein GS; Ortiz A
Contraception; 1977 Jun; 15(6):679-91. PubMed ID: 891194
[TBL] [Abstract][Full Text] [Related]
12. Pregnancies associated with sperm concentrations below 10 million/ml in clinical studies of a potential male contraceptive method, monthly depot medroxyprogesterone acetate and testosterone esters.
Barfield A; Melo J; Coutinho E; Alvarez-Sanchez F; Faundes A; Brache V; Leon P; Frick J; Bartsch G; Weiske WH; Brenner P; Mishell D; Bernstein G; Ortiz A
Contraception; 1979 Aug; 20(2):121-7. PubMed ID: 487815
[TBL] [Abstract][Full Text] [Related]
13. Sperm function in Indonesian men treated with testosterone enanthate.
Arsyad KM
Int J Androl; 1993 Dec; 16(6):355-61. PubMed ID: 8132379
[TBL] [Abstract][Full Text] [Related]
14. Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment.
Soufir JC; Jouannet P; Marson J; Soumah A
Acta Endocrinol (Copenh); 1983 Apr; 102(4):625-32. PubMed ID: 6221496
[TBL] [Abstract][Full Text] [Related]
15. Effect of long-term testosterone oenanthate administration on male reproductive function: clinical evaluation, serum FSH, LH, testosterone, and seminal fluid analyses in normal men.
Mauss J; Börsch G; Bormacher K; Richter E; Leyendecker G; Nocke W
Acta Endocrinol (Copenh); 1975 Feb; 78(2):373-84. PubMed ID: 1172906
[TBL] [Abstract][Full Text] [Related]
16. Suppression of spermatogenesis by testosterone enanthate in Thai men.
Aribarg A; Sukcharoen N; Chanprasit Y; Ngeamvijawat J; Kriangsinyos R
J Med Assoc Thai; 1996 Oct; 79(10):624-9. PubMed ID: 8996996
[TBL] [Abstract][Full Text] [Related]
17. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
Bebb RA; Anawalt BD; Christensen RB; Paulsen CA; Bremner WJ; Matsumoto AM
J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
[TBL] [Abstract][Full Text] [Related]
18. Is high dosage testosterone an effective male contraceptive agent?
Matsumoto AM
Fertil Steril; 1988 Aug; 50(2):324-8. PubMed ID: 3396702
[TBL] [Abstract][Full Text] [Related]
19. Suppression of human spermatogenesis by testosterone implants.
Handelsman DJ; Conway AJ; Boylan LM
J Clin Endocrinol Metab; 1992 Nov; 75(5):1326-32. PubMed ID: 1430094
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial with levo-norgestrel and testosterone oenanthate for male fertility control.
Føgh M; Corker CS; McLean H; Hunter WM; Petersen IB; Philip J; Schou G; Skakkebaek NE
Acta Endocrinol (Copenh); 1980 Oct; 95(2):251-7. PubMed ID: 6776755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
